First Eagle Investment Management LLC Acquires 27,906 Shares of Artivion, Inc. (NYSE:AORT)

First Eagle Investment Management LLC grew its holdings in Artivion, Inc. (NYSE:AORT) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 598,148 shares of the company’s stock after acquiring an additional 27,906 shares during the period. First Eagle Investment Management LLC owned about 1.43% of Artivion worth $15,342,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in AORT. nVerses Capital LLC purchased a new position in Artivion in the 2nd quarter worth approximately $28,000. GAMMA Investing LLC boosted its position in shares of Artivion by 38.6% during the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after acquiring an additional 505 shares during the last quarter. RiverPark Advisors LLC purchased a new position in Artivion during the second quarter valued at $55,000. Register Financial Advisors LLC purchased a new position in Artivion during the first quarter valued at $114,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in Artivion by 291.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after acquiring an additional 4,154 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AORT. Oppenheimer raised their price objective on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus raised their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research note on Friday, August 9th. Finally, Lake Street Capital increased their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd.

Insiders Place Their Bets

In other news, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total value of $238,420.20. Following the sale, the vice president now owns 34,116 shares of the company’s stock, valued at $863,475.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, VP Matthew A. Getz sold 9,420 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $25.31, for a total transaction of $238,420.20. Following the completion of the sale, the vice president now directly owns 34,116 shares of the company’s stock, valued at approximately $863,475.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the transaction, the director now owns 34,159 shares of the company’s stock, valued at approximately $853,633.41. The disclosure for this sale can be found here. Insiders sold 24,679 shares of company stock valued at $626,518 over the last three months. 8.10% of the stock is owned by company insiders.

Artivion Stock Down 1.0 %

Shares of NYSE:AORT opened at $24.97 on Thursday. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -104.04 and a beta of 1.74. Artivion, Inc. has a 12 month low of $12.16 and a 12 month high of $29.24. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The company has a 50-day moving average price of $26.10 and a 200 day moving average price of $23.59.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. As a group, equities research analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current year.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.